A Study of CDX-622 in Participants With Mild to Moderate Asthma
ConditionMild to Moderate Asthma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorCelldex Therapeutics
About this trial
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Eligibility criteria
Qualifiers
Males and females, ≥ 18 years of age
Diagnosis of mild to moderate asthma for at least 12 months
Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal
Airway reversibility ≥ 12% and 200 mL improvement in FEV1
Disqualifiers
Females who are pregnant or nursing
Pulmonary disease other than asthma
Systemic diseases with elevated eosinophils other than asthma
Hospitalization for treatment of asthma in the past 12 months or required oral corticosteroids due to asthma within the past 6 months
Trial design
Treatments tested in this trial
- CDX-622
Treatment groups
12 Participants
are divided into 1 treatment groupLocations
4University of California, San Francisco94143, San FranciscoCalifornia, United States
The University of Kansas Medical Center66160, Kansas CityKansas, United States
Brigham and Women's Hospital02115, BostonMassachusetts, United States
University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC15213, PittsburghPennsylvania, United States
Sponsors and collaborators
Celldex Therapeutics
Lead sponsor
Source ClinicalTrials.gov